日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

靶向激活的 PI3K/mTOR 信号可克服激素受体阳性乳腺癌临床前模型中对基于 CDK4/6 的疗法的获得性耐药性

Neil A O'Brien, Martina S J McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J Slamon

TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2

TMEM16A/ANO1 抑制可改善对 EGFR 和 HER2/ERBB2 抗体介导靶向治疗的反应

Sucheta Kulkarni, Anke Bill, Neal R Godse, Nayel I Khan, Jason I Kass, Kevin Steehler, Carolyn Kemp, Kara Davis, Carol A Bertrand, Avani R Vyas, Douglas E Holt, Jennifer R Grandis, L Alex Gaither, Umamaheswar Duvvuri

ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer

ANO1/TMEM16A 与 EGFR 相互作用,并与头颈癌对 EGFR 靶向治疗的敏感性相关

Anke Bill, Abraham Gutierrez, Sucheta Kulkarni, Carolyn Kemp, Debora Bonenfant, Hans Voshol, Umamaheswar Duvvuri, L Alex Gaither

Small molecule-facilitated degradation of ANO1 protein: a new targeting approach for anticancer therapeutics

小分子促进 ANO1 蛋白降解:一种新的抗癌治疗靶向方法

Anke Bill, Michelle Lynn Hall, Jason Borawski, Catherine Hodgson, Jeremy Jenkins, Philippe Piechon, Oana Popa, Christopher Rothwell, Pamela Tranter, Scott Tria, Trixie Wagner, Lewis Whitehead, L Alex Gaither

MK-STYX, a catalytically inactive phosphatase regulating mitochondrially dependent apoptosis

MK-STYX,一种催化失活的磷酸酶,调节线粒体依赖性细胞凋亡

Natalie M Niemi, Nathan J Lanning, Jeff A Klomp, Stephen W Tait, Yong Xu, Karl J Dykema, Leon O Murphy, L Alex Gaither, H Eric Xu, Kyle A Furge, Douglas R Green, Jeffrey P MacKeigan